Prognostic significance of serum soluble DR5 levels in small-cell lung cancer

被引:5
作者
Wan, Zhenfa [1 ]
Zhang, Xiaoshan [2 ]
Yu, Xinshuang [3 ]
Hou, Yong [3 ]
机构
[1] Fourth Hosp Jinan City, Dept Med Imaging, Jinan 250014, Shandong, Peoples R China
[2] Weihaiwei Peoples Hosp, Dept Med Imaging, Weihai 264200, Shandong, Peoples R China
[3] Shandong Prov Qianfoshan Hosp, Dept Radiat Oncol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China
来源
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES | 2019年 / 16卷 / 03期
基金
中国国家自然科学基金;
关键词
Small-cell lung cancer; soluble death receptor 5; biomarker; treatment responses; overall survival; APOPTOSIS-INDUCING LIGAND; TRAIL DEATH RECEPTORS; INTERNATIONAL-ASSOCIATION; TUMOR; EXPRESSION; IDENTIFICATION; THERAPY;
D O I
10.7150/ijms.28814
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The death receptor 5 (DR5) is a member of the tumor necrosis factor receptor superfamily that can transduce the apoptosis signal in cells. This study assessed serum levels of soluble death receptor 5 (sDR5) in small-cell lung cancer (SCLC) patients compared with those in healthy controls. Clinicopathological features of patients, treatment responses, and overall survival of patients were also recorded and analyzed. The sDR5 levels were analyzed using ELISA in 50 healthy controls and 82 SCLC patients before and after first-line chemotherapy. The statistical data showed that pre-treatment levels of serum sDR5 in SCLC patients were higher than those of healthy controls (P<0.001). Pre-treatment levels of serum sDR5 were significantly associated with smoking history of patients, Veterans Administration Lung Study Group (VALSG) stage, tumor size, and lymph node (N) metastasis (P=0.028, 0.001, 0.028, and 0.01, respectively). After treatment with the first-line chemotherapy, the post-treatment levels of serum sDR5 were obviously decreased (P<0.001), and correlated with treatment responses (P<0.001), although there was no significant difference in their pretreatment sDR5 levels (P=0.62). Cox proportional hazard analysis demonstrated that the post-treatment levels of serum sDR5, VALSG stage, and PS status were all independent predictors for overall survival of patients. The results from the current study indicate that serum level of sDR5 could be further confirmed as a biomarker to predict treatment responses and survival of SCLC patients.
引用
收藏
页码:403 / 408
页数:6
相关论文
共 50 条
[21]   Detection and significance of small-cell lung cancer serum protein markers using MALDI-TOF-MS [J].
Li, Zhihua ;
Tang, Chuanhao ;
Li, Xiaoyan ;
Li, Jianjie ;
Wang, Weixia ;
Qin, Haifeng ;
Xu, Bin ;
Chen, Jian ;
Gao, Hongjun ;
He, Kun ;
Liu, Xiaoqing .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01) :929-936
[22]   Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis [J].
Zhang, Xiuxiu ;
Guo, Mengfei ;
Fan, Jinshuo ;
Lv, Zhilei ;
Huang, Qi ;
Han, Jieli ;
Wu, Feng ;
Hu, Guorong ;
Xu, Juanjuan ;
Jin, Yang .
CANCER BIOMARKERS, 2016, 16 (03) :415-423
[23]   Clinical significance of serum soluble death receptor 5 concentration in locally advanced non-small cell lung cancer patients [J].
Yu, Xinshuang ;
Du, Juan ;
Zhai, Chunjuan ;
Zhang, Jiandong ;
Li, Guangyun ;
Dong, We ;
Xu, Deguo ;
Liu, Fengjun ;
Liu, Zhen ;
Tian, Yuan ;
Song, Meijuan ;
Ju, Ying ;
Li, Baosheng .
ONCOLOGY LETTERS, 2014, 8 (03) :1333-1339
[24]   Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer [J].
Minami, Seigo ;
Ogata, Yoshitaka ;
Ihara, Shouichi ;
Yamamoto, Suguru ;
Komuta, Kiyoshi .
LUNG CANCER-TARGETS AND THERAPY, 2016, 7 :35-44
[25]   Staging and clinical prognostic factors for small-cell lung cancer [J].
Argiris, A ;
Murren, JR .
CANCER JOURNAL, 2001, 7 (05) :437-447
[26]   The prognostic role of PET/CT in small-cell lung cancer [J].
Budak, E. ;
Yanarates, A. ;
Akgun, A. .
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 39 (01) :9-13
[27]   Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer [J].
Liu, Chao ;
Yao, Yao ;
Wang, Wei .
MEDICAL ONCOLOGY, 2014, 31 (10) :1-6
[28]   The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer [J].
Yildiz, Ramazan ;
Benekli, Mustafa ;
Buyukberber, Suleyman ;
Kaya, Ali Osman ;
Ozturk, Banu ;
Yaman, Emel ;
Berk, Veli ;
Coskun, Ugur ;
Yamac, Deniz ;
Sancak, Banu ;
Uner, Aytug .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (10) :1471-1476
[29]   Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients [J].
Jiang, Da ;
Shi, Jian ;
Yuan, Meng ;
Duan, Xiaoyang ;
Li, Lihua ;
Li, Qian .
CELLULAR AND MOLECULAR BIOLOGY, 2018, 64 (06) :71-76
[30]   Expression of DR5 and c-FLIP proteins as novel prognostic biomarkers for non-small cell lung cancer patients treated with surgical resection and chemotherapy [J].
Zheng, Hongmei ;
Zhang, Yuting ;
Zhan, Yuting ;
Liu, Sile ;
Lu, Junmi ;
Wen, Qiuyuan ;
Fan, Songqing .
ONCOLOGY REPORTS, 2019, 42 (06) :2363-2370